Assenagon Asset Management S.A. Lowers Stake in Catalent, Inc. (NYSE:CTLT)

Assenagon Asset Management S.A. reduced its holdings in shares of Catalent, Inc. (NYSE:CTLT) by 76.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 439,400 shares of the company’s stock after selling 1,436,429 shares during the period. Assenagon Asset Management S.A. owned 0.24% of Catalent worth $19,742,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of CTLT. Cetera Advisor Networks LLC increased its stake in Catalent by 7.1% during the 1st quarter. Cetera Advisor Networks LLC now owns 1,953 shares of the company’s stock valued at $217,000 after purchasing an additional 130 shares in the last quarter. Mackay Shields LLC increased its stake in Catalent by 0.6% during the 1st quarter. Mackay Shields LLC now owns 25,749 shares of the company’s stock valued at $2,856,000 after purchasing an additional 149 shares in the last quarter. Wetherby Asset Management Inc. increased its stake in Catalent by 5.1% during the 1st quarter. Wetherby Asset Management Inc. now owns 5,023 shares of the company’s stock valued at $557,000 after purchasing an additional 243 shares in the last quarter. Bessemer Group Inc. increased its stake in Catalent by 3.8% during the 2nd quarter. Bessemer Group Inc. now owns 6,801 shares of the company’s stock valued at $295,000 after purchasing an additional 252 shares in the last quarter. Finally, Nissay Asset Management Corp Japan ADV increased its stake in Catalent by 1.2% during the 4th quarter. Nissay Asset Management Corp Japan ADV now owns 21,164 shares of the company’s stock valued at $953,000 after purchasing an additional 252 shares in the last quarter.

Catalent Stock Performance

Shares of NYSE CTLT opened at $56.48 on Thursday. The firm has a 50 day moving average of $55.69 and a 200 day moving average of $47.13. The company has a current ratio of 2.48, a quick ratio of 1.73 and a debt-to-equity ratio of 1.34. The firm has a market capitalization of $10.21 billion, a price-to-earnings ratio of -8.31, a price-to-earnings-growth ratio of 3.57 and a beta of 1.20. Catalent, Inc. has a 12-month low of $31.45 and a 12-month high of $68.08.

Catalent (NYSE:CTLT) last announced its earnings results on Friday, February 9th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.02) by ($0.22). Catalent had a negative net margin of 29.91% and a negative return on equity of 2.43%. The business had revenue of $1.03 billion for the quarter, compared to the consensus estimate of $1.01 billion. During the same quarter last year, the firm posted $0.62 earnings per share. The business’s quarterly revenue was down 10.2% compared to the same quarter last year. On average, research analysts anticipate that Catalent, Inc. will post 0.48 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the stock. StockNews.com assumed coverage on shares of Catalent in a research note on Tuesday. They set a “sell” rating for the company. Royal Bank of Canada restated a “sector perform” rating and set a $63.50 price objective on shares of Catalent in a research note on Tuesday, February 20th. UBS Group reiterated a “neutral” rating and issued a $63.50 price target (up from $58.00) on shares of Catalent in a research note on Tuesday, February 6th. Barclays lifted their price target on shares of Catalent from $45.00 to $47.00 and gave the stock an “equal weight” rating in a research note on Thursday, January 25th. Finally, Stephens reiterated an “equal weight” rating and issued a $63.50 price target on shares of Catalent in a research note on Tuesday, February 6th. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $52.46.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.